Roche Secures Haosen Pharma, Breaking Waves in Innovative Drug Ocean

Haosen Pharmaceutical Group Limited announced a licensing agreement with Roche regarding HS-20110. This drug is an ADC targeting CDH17 with a payload of a clinically validated TOPOi. Haosen Pharma granted Roche exclusive rights outside Mainland China, Hong Kong, Macao, and Taiwan to develop and commercialize HS-20110. This marks another significant overseas licensing deal for Haosen Pharma, involving a payment of $80 million upfront with additional milestone payments and potential sales royalties. This collaboration highlights the hot trend in the global ADC sector. With policy support, capital infusion, and demand driving the sector, companies with international vision and strong research capabilities…